CymaBay Therapeutics Overview

  • Year Founded
  • 1988

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 101

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $3.9B

CymaBay Therapeutics General Information

Description

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).

Contact Information

Website
www.cymabay.com
Formerly Known As
Metabolex
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 7601 Dumbarton Circle
  • Fremont, CA 94555
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 7601 Dumbarton Circle
  • Fremont, CA 94555
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CymaBay Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
21. Merger/Acquisition 22-Mar-2024 $3.9B Completed Generating Revenue
20. 2PO 12-Sep-2023 Completed Generating Revenue
19. 2PO 24-Jan-2023 Completed Generating Revenue
18. 2PO 19-Jul-2017 Completed Generating Revenue
17. PIPE 19-Jul-2017 Completed Generating Revenue
16. 2PO 15-Jul-2015 Completed Generating Revenue
15. IPO 27-Jan-2014 Completed Profitable
14. Debt - General 11-Dec-2013 Completed Profitable
13. Later Stage VC 31-Oct-2013 $30.2M $249M Completed Profitable
12. Later Stage VC 10-Nov-2009 $5.58M $219M Completed Generating Revenue
To view CymaBay Therapeutics’s complete valuation and funding history, request access »

CymaBay Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with
Drug Discovery
Fremont, CA
101 As of 2023

South San Francisco, CA
 

Gaithersburg, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CymaBay Therapeutics Competitors (93)

One of CymaBay Therapeutics’s 93 competitors is NGM Biopharmaceuticals, a Private Equity-Backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA
Altimmune Formerly VC-backed Gaithersburg, MD
Aclaris Therapeutics Formerly VC-backed Wayne, PA
Galectin Therapeutics Corporation Norcross, GA
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 93 competitors. Get the full list »

CymaBay Therapeutics Patents

CymaBay Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260207538-A1 Combinations for liver disease Pending 20-Dec-2024
US-20260060948-A1 Methods for treating liver disease Pending 31-Jul-2024
US-20260055055-A1 Process for making seladelpar Pending 31-Jul-2024
WO-2026030479-A1 Process for making seladelpar Pending 31-Jul-2024
WO-2026030533-A1 Seladelpar for use in treating liver disease Pending 31-Jul-2024 A61K31/192
To view CymaBay Therapeutics’s complete patent history, request access »

CymaBay Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CymaBay Therapeutics Former Investors (30)

Investor Name Investor Type Holding Investor Since Participating Rounds
Abbott Ventures Corporate Venture Capital Minority
Abingworth Venture Capital Minority
AllianceBernstein Asset Manager Minority
Alta Partners Venture Capital Minority
Avoro Capital Venture Capital Minority
You’re viewing 5 of 30 investors. Get the full list »

CymaBay Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

20.62 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view CymaBay Therapeutics’s complete esg history, request access »

CymaBay Therapeutics FAQs

  • When was CymaBay Therapeutics founded?

    CymaBay Therapeutics was founded in 1988.

  • Where is CymaBay Therapeutics headquartered?

    CymaBay Therapeutics is headquartered in Fremont, CA.

  • What is the size of CymaBay Therapeutics?

    CymaBay Therapeutics has 101 total employees.

  • What industry is CymaBay Therapeutics in?

    CymaBay Therapeutics’s primary industry is Drug Discovery.

  • Is CymaBay Therapeutics a private or public company?

    CymaBay Therapeutics is a Private company.

  • What is the current valuation of CymaBay Therapeutics?

    The current valuation of CymaBay Therapeutics is .

  • What is CymaBay Therapeutics’s current revenue?

    The current revenue for CymaBay Therapeutics is .

  • How much funding has CymaBay Therapeutics raised over time?

    CymaBay Therapeutics has raised $655M.

  • Who are CymaBay Therapeutics’s investors?

    Abbott Ventures, Abingworth, AllianceBernstein, Alta Partners, and Avoro Capital are 5 of 30 investors who have invested in CymaBay Therapeutics.

  • Who are CymaBay Therapeutics’s competitors?

    NGM Biopharmaceuticals, Altimmune, Aclaris Therapeutics, Galectin Therapeutics, and Immunocore Holdings are some of the 93 competitors of CymaBay Therapeutics.

  • When was CymaBay Therapeutics acquired?

    CymaBay Therapeutics was acquired on 22-Mar-2024.

  • Who acquired CymaBay Therapeutics?

    CymaBay Therapeutics was acquired by Gilead.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process